Tebubio and Apricell Announce Partnership to Advance 3D Cell Culture and Organoid Research
A new partnership has been established between Tebubio, a leading distributor of life science research reagents and services, and Apricell, an innovative company specializing in 3D cell culture technologies. This collaboration aims to broaden access to cutting-edge tools that support researchers working on 3D culture and organoid-based projects across Europe.
Apricell’s product portfolio aligns seamlessly with Tebubio’s mission to provide comprehensive solutions to the life science community. Among Apricell’s innovations, the 3-in-1TM and HTSphereTM Plates stand out as a versatile NAM platform designed to simplify complex 3D cell culture workflows. These hydrogel inserts, compatible with standard well plates, enable spheroid formation, ECM integration, drug testing, and downstream analysis—all within a single, user-friendly format.
The Apricell 3D tissue organoid culture plates are suitable for a wide range of assays and are compatible with standard laboratory imaging and automated liquid handling equipment, making them adaptable to various experimental setups. By integrating multiple steps of the 3D culture process, Apricell’s technology helps researchers streamline their workflows and obtain more physiologically relevant results.
Through this partnership, Tebubio will distribute Apricell’s products to laboratories across Europe, empowering scientists to build robust 3D cell culture and organoid models. These systems are increasingly vital for investigating complex biological processes and for screening the effects of modulators and potential therapeutic candidates. Moreover, 3D cell culture models are a crucial step towards lowering the number of animal experiments.
The collaboration between Tebubio and Apricell marks a step forward in making advanced 3D culture solutions more accessible to researchers, reinforcing the growing importance of physiologically relevant models in modern biomedical research.
About Apricell
Apricell aims at redefining the future of drug development by integrating human-relevant tissue models with intelligent data analytics. Apricell’s platform harnesses cutting-edge organoid and Organoid-on-a-Plate™ technologies to deliver high-throughput, predictive systems that enhance therapeutic discovery and minimize the risk of clinical trial failure.
Contact : Amir Seyfoori, CEO and Co-Founder at Apricell Biotechnology Inc. - info@apricell.com
About Tebubio
Tebubio facilitates Life Sciences Research every day, contributing to advance Science for a brighter future. Through our local offices located across Europe, we support Life Sciences and Biotechnology Researchers with a unique, holistic range of solutions enabling them to access cutting-edge solutions sourced from reputed global Life Sciences suppliers, carefully selected by our Scientific Team for their relevance and evaluated for their ethical and legal compliance.
Contact : Cyrielle Delafoy, Corporate Communications - marketing@tebubio.com